Pharmafile Logo
Pharmafocus logo
Advanced Search

Oncology

Showing 15 posts of 302 posts found.

Third application for Orion’s prostate cancer drug submitted by partner Bayer

September 23, 2024
Bayer, Cancer, Oncology, orion, prostate cancer

Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …

News
lungs

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients

August 27, 2024
Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …

News

New gastric & gastro-oesophageal junction cancer treatment VYLOY™ ▼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain

August 16, 2024
GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer

Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …

News
Press release

First oral treatment for hormone-sensitive prostate cancer recommended by NICE

August 15, 2024
Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer

Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …

News

China CDE clears Phase 3 Study of Lisafltoclax in Newlly Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome

August 13, 2024
Clinical Research, Research and Development Ascentage Pharma, Oncology

The China Centre for Drug Evaluation (CDE) has cleared the registrational phase 3 study of lisaftoclax in combination with azacitadine …

News
acute_leukemia-all

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy

August 12, 2024
Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells

Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …

News
Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

August 7, 2024
Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …

News
Brain picture

Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young adults and adolescents launched by UCLA Health

August 6, 2024
Research and Development Oncology, UCLA Health, adolescent cancer, brain tumour, cancer vaccine, clinical trial

Today, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have announced that they are launching a first-of-its-kind clinical trial to …

News

National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.

August 6, 2024
Research and Development BeiGene, National Institute of Healthcare and Excellence, Oncology, lymphoma, margina zone lymphoma, orphan disease

BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for treatment …

News
Press release

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

August 5, 2024
Research and Development GSK, Oncology, Reproductive health, endometrial cancer

PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …

News
Press release

Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour

August 2, 2024
Medical Communications Adaptimmune, Oncology, accelerated approval, engineered cell therapy, oncology, synovial sarcoma

Adaptimmune Therapeutics has announced today that the US Food and Drug Administration (FDA) has given accelerated approval for TECELRA (afamitresgene …

News

INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA

August 1, 2024
Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma

Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …

News
Press release

Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile

July 30, 2024
Mergers and Acquisitions Boehringer Ingelheim, Nerio Therapeutics, Oncology, immuno-oncology, oncology

Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio Therapeutics for up to $1.3bn, …

News

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI  in combination with MEKTOVI  for the treatment of adult patients with advanced non-small cell lung cancer  NSCLC) with a BRAFV600E mutation

July 29, 2024
Clinical Trial Services BRAF mutation, CHMP, EMA, Oncology, Pierre Fabre Laboratories, colorectal cancer, european studies, non-small cell lung cancer

Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee for Medicinal Products Human use …

News

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

July 29, 2024
Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma

Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026